Venous Stent B.V. Appoints Darren Spencer as Chief Executive Officer

1 June 2025

Venous Stent B.V. today announced the appointment of Darren Spencer as its new Chief Executive Officer.

Venous Stent B.V., a pioneering company in the development of next-generation iliac venous stents, today announced the appointment of Darren Spencer as its new Chief Executive Officer.

Spencer brings over 25 years of international leadership experience in cardiology and medical technology, with a proven track record of driving growth, leading successful clinical trials, and overseeing global product launch for multiple MedTech startups. Throughout his career, Spencer has held senior leadership roles across Europe and the US, spearheading sales, clinical affairs, and business development for companies that were later acquired by major global medtech leaders, including Boston Scientific, Medtronic, and Abbott. He has been instrumental in securing CE and FDA approvals, guiding first-in-human studies, and scaling businesses from early-stage ventures to multi-country operations.

Prior to joining Venous Stent B.V., Spencer served as Founder and CEO of ARTritech, and previously as Founder of DVSE Opus Ltd. He has also held senior roles at Bluegrass Vascular Inc, Atritech Inc., Ablation Frontiers Inc., and Cameron Health Inc., contributing to landmark acquisitions collectively valued at over $2 billion.

“Venous Stent B.V. is addressing a critical unmet need in venous disease treatment, and I am honoured to lead the company at such a pivotal stage,” said Darren Spencer. “Our technology has the potential to transform outcomes for patients with complex venous conditions, and I look forward to working with our team, partners, and investors to bring this innovation to market.”

Venous Stent B.V. is advancing the development of its proprietary iliac venous stent system, designed to address the anatomical challenges of deep venous disease such as May-Thurner syndrome, DVT, and NIVLS. The company is preparing for its upcoming first-in-human clinical trials and regulatory pathway in both Europe and the United States.